Envestnet Asset Management Inc. Reduces Position in Repligen Corporation (NASDAQ:RGEN)

Envestnet Asset Management Inc. lessened its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 0.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 106,255 shares of the biotechnology company’s stock after selling 187 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.19% of Repligen worth $13,520,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Utah Retirement Systems raised its holdings in shares of Repligen by 1.1% during the fourth quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company’s stock valued at $1,338,000 after acquiring an additional 100 shares in the last quarter. Peapack Gladstone Financial Corp raised its holdings in shares of Repligen by 5.2% during the fourth quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company’s stock valued at $301,000 after acquiring an additional 103 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 124 shares in the last quarter. Coldstream Capital Management Inc. raised its holdings in shares of Repligen by 6.3% during the fourth quarter. Coldstream Capital Management Inc. now owns 2,332 shares of the biotechnology company’s stock valued at $336,000 after acquiring an additional 138 shares in the last quarter. Finally, Treasurer of the State of North Carolina raised its holdings in shares of Repligen by 0.7% during the fourth quarter. Treasurer of the State of North Carolina now owns 24,500 shares of the biotechnology company’s stock valued at $3,527,000 after acquiring an additional 160 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Trading Down 6.3%

Repligen stock opened at $116.25 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79. Repligen Corporation has a one year low of $102.97 and a one year high of $182.52. The stock has a market capitalization of $6.53 billion, a PE ratio of -258.33, a price-to-earnings-growth ratio of 3.55 and a beta of 1.11. The business’s fifty day moving average is $124.65 and its 200 day moving average is $138.51.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The company had revenue of $169.17 million for the quarter, compared to analysts’ expectations of $163.65 million. During the same period last year, the firm posted $0.28 earnings per share. Repligen’s revenue was up 10.4% compared to the same quarter last year. On average, sell-side analysts predict that Repligen Corporation will post 1.72 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on RGEN shares. Canaccord Genuity Group decreased their target price on Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a report on Wednesday, April 16th. Barclays assumed coverage on Repligen in a report on Tuesday, June 24th. They issued an “overweight” rating and a $150.00 price objective for the company. Wolfe Research upgraded Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price objective for the company in a report on Tuesday, April 29th. Wall Street Zen downgraded Repligen from a “buy” rating to a “hold” rating in a report on Sunday, June 29th. Finally, JPMorgan Chase & Co. decreased their price objective on Repligen from $200.00 to $190.00 and set an “overweight” rating for the company in a report on Tuesday, April 29th. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $170.75.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.